Stocktoria
LISATA THERAPEUTICS, INC. LSTA
LISATA THERAPEUTICS, INC. (LSTA) earns a Piotroski F-score of 1/9 (weak financial health). It pays a dividend yielding 1.07% (safety: no dividend). FY2025 revenue was $170,000 at a -9756.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LSTA | LISATA THERAPEUTICS, INC. | 1/9 | — | — | — |
| CLNN | Clene Inc. | 1/9 | — | — | — |
| SER | Serina Therapeutics, Inc. | 2/9 | — | — | — |
| BFRG | BullFrog AI Holdings, Inc. | 1/9 | — | — | — |
| ATNM | Actinium Pharmaceuticals, Inc. | 2/9 | — | — | — |
| IXHL | Incannex Healthcare Inc. | 2/9 | — | — | — |
| SILO | Silo Pharma, Inc. | 2/9 | -1.23 | — | — |
About LISATA THERAPEUTICS, INC.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
FAQ
Is LSTA financially healthy?
LISATA THERAPEUTICS, INC.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does LSTA pay a dividend, and is it safe?
Yes. LISATA THERAPEUTICS, INC. pays a dividend yielding about 1.07% with a None payout ratio, rated “no dividend” for safety.
How profitable is LSTA?
In FY2025, LISATA THERAPEUTICS, INC. had a net margin of -9756.5% and a return on equity of -111.7%.
What is the analyst price target for LSTA?
The average Wall-Street price target for LISATA THERAPEUTICS, INC. is $4.00, about 239.0% above the recent price, from 1 analysts.
Is LSTA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on LISATA THERAPEUTICS, INC.: a Piotroski F-score of 1/9, a dividend yield of 1.07%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.